European Commission Probes Sanofi for Possible Antitrust Violations Related to Flu Shots
French pharmaceutical company Sanofi said that European Commission (EC) officials carried out unannounced inspections at its premises in France and Germany as part of an investigation into its conduct in the seasonal influenza vaccine market.1 It is not clear whether the investigation has any impact beyond Europe, but Sanofi produces influenza vaccines for the U.S. […]
FDA Approves MenQuadfi Meningococcal Vaccine for Six-Week-Old Infants
The U.S. Food and Drug Administration (FDA) has licensed Sanofi’ SA’s four-valent MenQuadfi meningococcal vaccine for use in infants aged six weeks to 23 months old to prevent invasive meningococcal disease. Previously approved for children aged two and older, MenQuadfi is now the first meningococcal vaccine included on the U.S. Centers for Disease Control and […]
FDA Approves GSK’s 5-in-1 Meningococcal Vaccine
On Feb. 14, 2025, British pharmaceutical and biotechnology company GSK plc announced that the U.S. Food and Drug Administration (FDA) approved its 5-in-1 meningococcal vaccine PENMENVY for licensure and use in individuals aged 10 through 25 years. The vaccine targets five major serogroups of the bacterium Neisseria meningitidis (A, B, C, W, and Y), which […]